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Roux-en-Y bypass surgery is the most common bariatric
procedure currently performed in the United States for
medically complicated obesity. Although this leads to a
marked and sustained weight loss, we have identified
an increasing number of patients with episodes of
nephrolithiasis afterwards. We describe a case series of
60 patients seen at Mayo Clinic-Rochester that developed
nephrolithiasis after Roux-en-Y gastric bypass (RYGB),
including a subset of 31 patients who had undergone
metabolic evaluation in the Mayo Stone Clinic. The mean
body mass index of the patients before procedure was
57 kg/m2 with a mean decrease of 20 kg/m2 at the time of the
stone event, which averaged 2.2 years post-procedure. When
analyzed, calcium oxalate stones were found in 19 and mixed
calcium oxalate/uric acid stones in two patients.
Hyperoxaluria was a prevalent factor even in patients
without a prior history of nephrolithiasis, and usually
presented more than 6 months after the procedure.
Calcium oxalate supersaturation, however, was equally high
in patients less than 6 months post-procedure due to
lower urine volumes. In a small random sampling of patients
undergoing this bypass procedure, hyperoxaluria was
rare preoperatively but common 12 months after surgery.
We conclude that hyperoxaluria is a potential complicating
factor of RYGB surgery manifested as a risk for calcium
oxalate stones.
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Nearly 20% of the United States population can be currently
described as obese (body mass index (BMI) 430 kg/m2),
including 11.5 million who are morbidly obese (BMI440 kg/
m2).1 No single dietary therapy or medication has been more
than modestly effective for sustainable weight loss. Further,
approximately 5 million Americans have what is deemed
medically complicated obesity (e.g., weight-related comor-
bidities such as concurrent diabetes mellitus, hypertension,
sleep apnea, and/or other weight-related medical comorbid-
ities). As a consequence, increasing numbers of patients
choose surgical interventions to treat their illness, including
Roux-en-Y Gastric Bypass (RYGB) procedures, the most
common bariatric operation in the United States.2–7 RYGB
procedures result in marked, sustained weight loss and an
improvement in abnormal glucose homeostasis, insulin
resistance, sleep apnea, hypertension, and cardiovascular risk
factors.8–12 Although both short-term and long-term com-
plications of the RYGB procedure have been recognized,
including osteopenia, osteomalacia, and more rarely neuro-
logical disorders,13–19 the procedure has been deemed
relatively safe and effective. In a consecutive cohort of 191
RYGB patients from our institution,20 hospital mortality was
0.5% (1/191), and postsurgical hospital morbidity occurred
in 10.5% (20/191) of all patients. Good long-term weight loss
was achieved, and patients adapted well to the required new
eating habits. Overall, 72% of the patients achieved and
maintained a weight loss of 50% or more of their
preoperative excess body weight 3 years after the operation.
Because RYGB is felt to be a safe, effective, and durable
procedure for most patients with medically complicated
obesity, in the United States it is considered the procedure of
choice for patients receiving bariatric surgery to treat
medically complicated obesity. Consequently, in the United
States, the number of procedures has increased from an
estimated 14 000 in 1998 to 108 000 in 2003.21
Until very recently, an increased incidence of renal stones
in patients after RYGB procedures had not been appreciated.
Furthermore, extensive testing for abnormalities in urine
analytes that would characterize those at risk for develop-
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ment of nephrolithiasis has not been carried out in patients
after RYGB. A small series of 23 patients with hyperoxaluria
after RYGB was reported recently from our institution.22 In
this study, we collected detailed metabolic data from a larger
cohort of RYGB patients with nephrolithiasis (n¼ 60,
including the previous 23 patients), in order to delineate
the potential urinary lithogenic factors and response to
treatment strategies. To further assess the prevalence and
rapidity of onset of potentially lithogenic abnormalities in
urine, we conducted a pilot cross-sectional study of urinary
oxalate excretion among obese patients before and after
RYGB. Our studies show that nephrolithiasis is more
common than previously recognized in patients undergoing
RYGB surgery, and that abnormalities in the lithogenic
profile of urine can occur within 12 months of the procedure
in a significant percentage of patients.
RESULTS
Of the 60 patients identified who underwent RYGB and
subsequently developed nephrolithiasis, 30 patients were
women and 30 were men. Mean time to development of first
stone post-RYGB was 2.9 years (range: 1 month–13 years).
Twenty-four patients underwent standard RYGB and 36
patients underwent distal RYGB. Because the percentage of
patients who undergo the distal procedure at Mayo Clinic is
approximately 1/5th that of the standard RYGB (Table 1), the
risk of nephrolithiasis may be greater after distal RYGB.
Of these 60 post-RYGB patients with nephrolithiasis,
31 patients had been seen in the Mayo Stone Clinic and
therefore had detailed urinary data for further analysis
(Table 2 and Figure 1). Among this group, the prevalence of
pre-existing nephrolithiasis was relatively high (11/31; 32%).
The first patient was seen in 1994, but the majority (17) was
Table 1 | Mayo Clinic, Rochester, nephrolithiasis cases identified after RYGB
Standard Distal
Mayo RYGB patients 1985–2004 1178 258
Mayo RYGB patients with Mayo diagnosis codes of nephrolithiasis, oxalate nephropathy,
enteric hyperoxaluria (1985–2004)
14 9
Mayo RYGB survey responders with nephrolithiasis events elsewhere (survey sent only to
Mayo distal RYGB patients 1985–2004; 168 out of 258 responded)
— 27
Additional Mayo and non-Mayo post-RYGB nephrolithiasis cases identified via stone clinic
referrals (through May 2006)
10 0
Total known cases of nephrolithiasis after RYGB seen at Mayo (through May 2006) 24 36
Total nephrolithiasis cases after RYGB with available metabolic data 15 16
RYGB, Roux-en-Y gastric bypass.
Table 2 | 24 h urinary composition in patients presenting with nephrolithiasis after standard and distal RYGB
RYGB – standard and distal (n=31) RYGB – standard (n=15) RYGB – distal (n=16)
Reference range Mean (s.d.) Mean (range) Mean (range)
Male/female 14/17 7/8 7/9
Age (years) 47.8 (8.2) 49.2 (34–60) 46.3 (30–61)
Time to first stone (years) 2.2 (2.7) 2.1 (0.2–11.0) 1.9 (2.3.2–7.0)
BMI pre kg/m2 57.0 (12.4) 51.8 (41.7–83.8) 62.2* (49.8–102.7)
Mean BMI loss kg/m2 17.5 (8.9) 15.3 (6.2–43.5) 9.9 (19.6–40.3)
no. with stones before 9/31 (29%) 6/15 (40%) 3/16 (21%)
Volume (ml) 1612 (687) 1583 (486–2939) 1643 (502–3573)
PH 5.6 (0.6) 5.7 (5.0–6.8) 5.6 (4.8–7.0)
Citrate 4B400 mg/24 h# 394 (361) 518 (0–1176) 269 (0–853)
Oxalate 0.11–0.46 mmol/24 h 0.66 (0.41) 0.61 (0.24–1.19) 0.71 (0.07–1.80)
Calcium 20–275 mg/24 h 132 (96) 115 (37–241) 149 (43–504)
Uric Acid o750 mg/24 h 456 (207) 479 (213–708) 435 (153–1002)
Magnesium 75–150 mg/24 h 98 (47) 100 (31–227) 96 (40–149)
Phosphorous o1100 mg/24 h 893 (450) 717 (38–1513) 1069* (610–2059)
Sodium 40–217 mmol/24 h 180 (76) 168 (74–396) 192 (86–299)
Potassium 30–90 mmol/24 h 43 (18) 38 (24–56) 46 (21–90)
Chloride 10–250 mmol/24 h 162 (56) 144 (75–209) 170 (58–265)
Sulfate o47 mmol/24 h 12.1 (5.2) 12.6 (6.0–24.0) 12.1 (4.0–24.0)
CaOx SS o1.77 DGa 2.23 (0.52) 2.02 (1.14–2.84) 2.34 (1.72–2.92)
BR SS o0.21 DGa 1.47 (1.56) 1.41 (2.75–0.31) 1.49 (5.22–1.10)
UA SS o1.04 DGa 0.83 (3.40) 0.81 (4.73–4.51) 0.85 (6.27–4.64)
Creat Clearance (ml/min) 89 (25) 99 (75–145) 83 (49–124)
BMI, body mass index; BR, brushite; CaOx, calcium oxalate; DG, delta Gibbs unit; RYGB, Roux-en-Y gastric bypass; SS, supersaturation; UA, uric acid.
aDG is negative for undersaturated solutions, and positive for saturated solutions. Any value greater that the reference mean is considered at risk for the respective crystal
type.
*Po0.05 standard vs distal.
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seen in the last 2 years. Mean age at time of RYGB was 48 years
(range 30–61 years), preprocedure BMI was 57712 kg/m2,
time to stone event was 2.272.7 years, and decrease in BMI at
the time of stone event 17.578.9 kg/m2. Stone type was
analyzed in the Mayo Clinic Metals Lab for 21 patients
revealing (CaOx) in 19 patients, and mixed CaOx and uric
acid (UA) in two patients. Urinary CaOx supersaturation (SS)
was increased to 2.2370.50 delta Gibbs units (DG) (normal
population reference mean 1.77 DG), whereas SS for UA was
low (0.8373.40 DG), and absent for calcium phosphate
(1.4771.56 DG). Hyperoxaluria was a common contribut-
ing factor present in 17/31 patients (mean urinary oxalate
0.6670.40 mM/24 h).
Because the distal RYGB is associated with a shorter
absorptive surface and might lead to a greater risk of
malabsorption, patients were divided into standard (n¼ 15)
and distal (n¼ 16) RYGB groups (Table 2). The major
difference between the two subgroups was a greater presurgical
BMI in the distal RYGB patients (62 vs 52 kg/m2), which is not
surprising because greater BMI has been a criterion for this
more aggressive procedure. Twenty-four-hour citrate excre-
tion was modestly less in the distal group (2697308 vs
5197388 mg; P¼ 0.08), whereas phosphorous excretion was
significantly higher; other parameters including oxalate
excretion did not appear to differ. Mean creatinine clearance
in the entire cohort was not decreased (89 ml/min) but was
less than 60 ml/min in three individuals (Figure 1). Eleven
patients had a history of stones before RYGB. When analyzed
as a group, those with a prior history of stones (n¼ 11) when
compared with those without (n¼ 20) demonstrated a
possible trend toward higher excretions of calcium
(153728 vs 120721 mg/24 h; P¼ 0.18) and citrate
(4917116 vs 378784 mg; P¼ 0.22), but lower excretion of
oxalate (0.5570.08 vs 0.7370.12 mM/24 h; P¼ 0.10). How-
ever, none of these trends reached statistical significance
(Figure 2).
Ten patients had follow-up visits to our stone clinic after
being placed on treatments that varied but typically included
low-fat, low-oxalate diets, and use of calcium binders with
meals. Overall, urinary CaOx SS decreased from 2.6970.25
to 2.1270.37 DG (Po0.01), even though mean urinary
oxalate excretion actually increased in the group as a whole
(0.7770.34–0.8670.38 mM/24 h). When examined by indi-
vidual, however, urinary oxalate excretion decreased in many
(5/9 standard and 3/5 distal RYGB patients), and CaOx SS
decreased in all six patients for whom data were available to
calculate the CaOx SS (although for only one patient did
CaOx SS decrease below the reference mean while on a
treatment program).
At the time of this report, a single male patient with a
history of CaOx stones had been followed in the Mayo Stone
Clinic before and after the RYGB procedure. Preoperatively,
hypercalciuria, hyperuricosuria, and mild hyperoxaluria were
all present and accordingly he was treated with a combina-
tion of thiazide diuretics, allopurinol, and dietary advice.
Although these medications were stopped at the time of the
RYGB, urinary calcium, oxalate, and UA were all in the
normal range 5 months postoperatively. By 11 months
postoperatively, urinary oxalate excretion had increased to
0.56 mM/24 h and was at 0.66 mM/24 h 15 months post-
operatively. Based on this anecdotal observation, we exam-
ined urinary oxalate excretion as a function of time after
RYGB in the group of patients with nephrolithiasis. In
general, 24 h urinary oxalate excretion was low in those
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Figure 1 | Urinary chemistries in patients presenting with nephrolithiasis after RYGB. Twenty-four urine values for volume, pH, citrate,
calcium, oxalate, and creatinine clearance are depicted with superimposed box plots for each analyte. Patients are divided into those
undergoing distal and standard RYGB. Horizontal lines indicate upper (oxalate, calcium, CaOx SS) or lower (citrate) limits of reference ranges for
selected analytes. Not all patients had sufficient data to calculate CaOx SS.
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patients that presented and were studied in the early
postoperative period, but increased thereafter, although
CaOx SS was equally increased across all times (Figure 3).
Patients were therefore divided into an early postoperative
group (defined as those less than 6 months after RYGB,
n¼ 8) and those further out from the procedure
(46 months; n¼ 23). As expected, the early group had lost
less weight (BMI change 1073 vs 20710 kg/m2). Urinary
oxalate excretion was increased in a greater percentage of
patients that presented with stones 46 months after RYGB,
as compared with thoseo6 months after RYGB, with overall
higher oxalate excretions (0.7470.42 vs 0.4470.24 mM/24 h;
Po0.05). However, CaOx SS was equally high in both groups
(2.2870.19 vs 2.2270.58 DG), largely owing to a lower 24 h
urine volume (12237413 vs 17477812 ml; Po0.05) as well
as a lower magnesium excretion among the patients in the
earlier postoperative period.
We could not determine, from these observations in a
stone clinic population, how common hyperoxaluria might
be before or after RYGB. Therefore, we performed a small
cross-sectional study of patients seen at Mayo Clinic pre- and
post-RYGB surgery. This included patients undergoing
preoperative assessment (n¼ 20) and follow-up visits after
surgery at 6 months (n¼ 8) or 12 months (n¼ 13). Patients
were recruited randomly over the course of several weeks in
order to represent all three time periods. At baseline in this
obese population (mean BMI 4878 kg/m2), hyperoxaluria
was present in only 2/20 patients (group mean 0.35 mM/24 h)
and mean CaOx SS was below the reference mean (Table 3).
Changes in the urinary composition were minimal at 6
months, but in the 12-month group significant decreases in
urinary citrate and calcium were observed, as was an increase
in urinary oxalate (mean urinary oxalate 0.74 mM/24 h;
Table 3). At 12 months postoperatively, hyperoxaluria was
present in 7/13 subjects and the resulting SS for CaOx was
increased dramatically above the reference mean in 12 of 13
patients (mean CaOx SS of 2.3870.49 DG at 12 months vs
1.5170.78 DG at baseline; P¼ 0.009 for comparison of the
two groups; Figure 4). Therefore, the risk for CaOx stones
appears markedly increased in the group 1 year after RYGB as
compared with the preoperative group. Because obesity is a
known risk factor for renal stones, it is not surprising that
nephrolithiasis was commonly present preoperatively in
this RYGB patient population (14 of the 41 patients were
previous stone formers). However, even when these patients
with preexisting nephrolithiasis were removed from the
analysis, hyperoxaluria was present in five out of eight
patients at 12 months after RYGB (mean urinary oxalate
0.8370.46 mM/24 h).
DISCUSSION
In this paper, we report 60 patients that developed renal
stones after RYGB surgery. These include 23 patients from
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Figure 2 | Urinary chemistries in patients presenting with nephrolithiasis after RYGB divided into those without (No) or with (Yes)
a prior history of stones. Twenty-four urine values for volume, pH, citrate, oxalate, calcium, and CaOx SS are depicted with superimposed box
plots for each analyte. Horizontal lines indicate upper (oxalate, calcium, CaOx SS) or lower (citrate) limits of reference ranges for selected
analytes. Patients are divided into those without stones before RYGB and those with antecedent stones. Among those with a prior history
of stones, possible trends were for higher mean citrate (P¼ 0.22) and calcium (P¼ 0.18) excretions and lower oxalate excretions (P¼ 0.10),
although none reached statistical significance. Urinary CaOx SS were equally high in both groups. Not all patients had sufficient data
to calculate CaOx SS.
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Figure 3 | Oxalate excretion among patients that presented
with nephrolithiasis as a function of time since RYGB. Urinary
oxalate excretion was low in many patients early after RYGB (6/8
o6 months postoperative in the left panel), whereas CaOx SS was in
general high at all time points after the procedure (right panel).
Note log scale on the x axis; vertical line is at 6 months (0.5 years).
Not all patients had sufficient data to calculate CaOx SS. Urinary
oxalate levels were elevated in a greater percentage of patients
that presented with stones 46 months after RYGB (15/23) as
compared with those o6 months after RYGB (2/8), with overall
higher oxalate excretions (0.7470.42 vs 0.4470.24 mM/24 h; Po0.05).
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our previous study.22 A subset of 31 patients was seen in the
Mayo Stone Clinic and urinary data were available for
detailed analysis. Hyperoxaluria was a common risk factor in
these stone-forming patients, although low urinary volumes
and reduced 24 h urinary excretions of citrate and magne-
sium appear to be important contributing factors as well.
Even though the RYGB operation with a Roux limbo150 cm
in length is generally believed not to cause fat malabsorption,
these data suggest that hyperoxaluria may indeed occur, at
least in a subset, and represent a risk for CaOx nephro-
lithiasis. In fact, our pilot data among a cross-section of
randomly selected patients suggest that approximately half
may have significant hyperoxaluria 1 year after RYGB
(Figure 4). Urinary calcium excretion also tended to be low
in both stone-forming and non-stone-forming patients after
RYGB, also consistent with some degree of fat malabsorption.
A relatively high percentage of patients that presented with
nephrolithiasis after RYGB (10/31; 32%) had a prior history
of stones, perhaps because obesity is a risk factor for
nephrolithiasis23 or possibly because pre-existing nephro-
lithiasis increases the risk for stones after RYGB. However, a
similar percentage of patients in the random sample of
patients undergoing the procedure also had pre-existing
stones (14/41; 34%), suggesting that the obese population
undergoing RYGB is indeed enriched with stone formers. It is
also unclear how many of such patients with pre-existing
renal stones might experience a quiescent course after RYGB,
or the relative risk of stone occurrence/recurrence after other
forms of gastrointestinal surgery. Although obesity is
associated with increased oxalate excretion, the urinary
changes we observed are not likely to be due to obesity
alone. In a study from the United States,24 urinary oxalate
Table 3 | 24 h urinary composition of lithogenic substances in a cross-sectional sample of patients at baseline, 6 months, and
12 months after RYGB surgery
Baseline preoperative (n=20) 6 months postoperative (n=8) 12 months postoperative (n=13)
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Volume 1939 (762) 1409 (894) 1629 (823)
pH 5.95 (0.38) 5.81 (0.92) 5.76 (0.59)
Citrate 660 (277) 563 (449) 444 (376)
Oxalate 0.35 (0.18) 0.32 (0.15) *0.74 (0.44)
Calcium 206 (111) *111 (86) *112 (92)
UA 708 (255) *426 (108) *461 (166)
Magnesium 113 (55) 92 (58) 156 (126)
Phosphorous 1149 (580) *716 (227) 900 (266)
Sodium 199 (98) *118 (72) 171 (103)
Potassium 63 (21) *35 (11) 53 (34)
Chloride 188 (102) *114 (63) 171 (109)
Sulfate 24.7 (10.5) *12 (6.7) *15.9 (8.6)
CaOx SS 1.51 (0.78) 1.49 (1.31) *2.38 (0.49)
BR SS 0.31 (1.18) 1.38 (1.83) 0.92 (1.54)
UA SS 1.43 (2.81) 1.82 (4.06) 1.26 (3.63)
Creatinine clearance 117 (44) 110 (26) 99 (40)
BR, brushite; CaOx, calcium oxalate; SS, supersaturation; UA, uric acid.
*Po0.05 vs baseline; see Table 2 for normal reference ranges.
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Figure 4 | Urinary chemistries among patients that presented with nephrolithiasis after RYGB as a function of time after RYGB. Twenty-
four urine values for volume, pH, citrate, calcium, oxalate, and creatinine clearance are depicted with superimposed box plots for each analyte.
Horizontal lines indicate upper (oxalate, calcium, CaOx SS) or lower (citrate) limits of reference ranges for selected analytes. Patients were
divided in those less than 6 months vs greater than 6 months postoperative. Although oxalate levels were lower in the early postoperative
group, urinary CaOx SS were equally high in both groups. Horizontal lines indicate limits of reference range for individual analytes. Not all
patients had sufficient data to calculate CaOx SS.
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was increased in obese (4120 kg) men (0.37 vs 0.50 mM/
24 h) and obese (4100 kg) women (0.28 vs 0.37 mM),
whereas in a German report,25 oxalate levels were increased
in obese (BMI 430 kg/m2) women (0.45 vs 0.32 mM) but not
in obese (BMI 430 kg/m2) men (0.33 vs 0.36 mM). The
increases in urinary oxalate we observed after RYGB were in
general much higher (mean oxalate excretion 0.66 mM/ 24 h).
Further, the mean oxalate excretion among a random cross-
section of obese patients before RYGB surgery was only
0.3570.18 mM/24 h (Table 3). Finally, obesity is associated
with higher rather than lower excretions of calcium and
citrate.24,25
The findings in patients after RYGB may or may not
parallel observations in patients who had undergone previous
ileal or jejuno-ileal bypass procedures for hypercholesterole-
mia or medically complicated obesity, respectively, in whom a
markedly increased incidence of renal stones, nephrocalcino-
sis, and renal failure was observed.26–32 Jejuno-ileal bypass is a
more extensive, malabsorptive procedure, and hyperoxaluria is
secondary to hyperabsorption of oxalate from the bowel with
increased urinary excretion of oxalate by the kidney.32 In
contrast, RYGB as performed today is not a global malabsorp-
tive procedure,26 and although nephrolithiasis was a well-
known complication of the jejuno-ileal operation,33,34 until
recently it had not been recognized as a potential complication
of RYGB.22 Our results suggest that hyperoxaluria is indeed a
common underlying risk factor in those RYGB patients that do
develop stones, whereas hypocitraturia and a decreased 24-hr
urine volume is also a contributing factor.
Enteric hyperoxaluria, observed often in association with
fat malabsorption, is believed to develop when oxalates
derived from the diet are delivered to the colon uncomplexed
with calcium. This phenomenon is observed commonly when
disorders such as Crohn’s disease affect the ileum, or when
the ileum has been resected, leading to bile acid and fat
malabsorption. The mechanism by which RYGB patients
develop hyperoxaluria has yet to be determined, but it seems
likely that the length of the common channel may predispose
to clinically significant fat malabsorption in some, leading to
enteric hyperoxaluria. Previous studies have suggested that
the degree of hyperoxaluria corresponds with the degree of
steatorrhea,35 as observed in various disease conditions
associated with fat malabsorption, including inflammatory
bowel disease, ileal resection, and jejuno-ileal bypass.36–39 In
the one patient among our current series in whom it was
measured, 72 h fecal fat was increased (57 g), despite the
absence of diarrhea. Interestingly, none of the 31 patients
seen in stone clinic with nephrolithiasis after RYGB reported
symptoms of diarrhea. In a single case series, steatorrhea was
reported in 18 out of 45 patients after biliopancreatic bypass
for obesity, although clinical symptoms were not reported.40
Typical treatment strategies for enteric hyperoxaluria are
prescription of a low-fat, low-oxalate diet, generous fluid
intake, and use of oral oxalate binders such as calcium.
Previous studies have demonstrated a decrease in urinary
oxalate excretion when dietary calcium content was increased
or when oral calcium supplements were prescribed among
patients with enteric hyperoxaluria secondary to inflamma-
tory bowel disease, ileal resection, or jejuno-ileal by-
pass.37,38,41 These dietary modifications, however, may be
difficult to achieve. Although none of the patients evaluated
in our stone clinic felt they had diarrhea, many have learned
to alter their eating patterns toward many small meals in
order to avoid symptoms. Dietary oxalate is found in green
leafy vegetables, chocolate, nuts, strawberries, and soy
products;42 however, accurate information regarding the
oxalate content in particular foods is difficult to find, because
it is not measured routinely or listed on food labels. In
addition, published values are general estimates because
oxalate content can vary depending on conditions during
growth or manufacture. Therefore, avoiding high oxalate
intake can be a difficult proposition. Further, use of calcium
as an oxalate binder can be challenging when the food is
ingested via frequent snacks as opposed to larger meals.
Studies to identify improved strategies to decrease urinary
oxalate levels among the ever-expanding pool of patients
undergoing RYGB surgery are clearly needed.
Endogenous intestinal flora utilize oxalate and could
thereby limit absorption.43 Oxalobacter formigenes, a normal
commensurate part of the human gut microflora, can
metabolize oxalate as an energy source; indeed, several
studies have suggested that colonization with O. formigenes
has a protective effect against increased oxalate excretion.44,45
Whether or not RYGB procedures alter colonization with this
organism is unknown. This point is pertinent because a
single study demonstrated decreased intestinal colonization
with these oxalate-degrading bacteria in patients after jejuno-
ileal bypass.46 Other intestinal bacteria could also alter
intestinal oxalate absorption, either via degradation or effects
on mucosal absorption. A recent study demonstrated that
oral administration of a preparation of lactic acid bacteria
reduced urinary oxalate excretion by a small but significant
percentage in a group of patients with enteric hyperoxaluria.
Oral administration of Oxalobacter or the active enzymes
represents another promising treatment strategy because rats
colonized with Oxalobacter changed from net colonic
absorbers of oxalate to net secretors.47
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Figure 5 | Changes in urinary oxalate and CaOx SS in a random
sample of patients both before and after RYGB. Oxalate was
increased above the upper limit of the reference range (horizontal
line, 0.46 mM/ 24 h) in two out of 20 patients preprocedure and in
seven out of 13 at 12 months. At 12 months, all but one patient had a
CaOx SS above the reference mean of 1.77 (horizontal line). P¼ 0.009
for comparison of CaOx SS between baseline and 12 months groups.
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The true prevalence of hyperoxaluria after RYGB is unknown
and would require larger prospective urine studies in non-stone
formers as well as stone formers. Our preliminary data in a
small cross-section of patients after RYGB suggest that
hyperoxaluria may be quite common (Figure 5). Given the
increasing use of this procedure primarily as a treatment for
morbid obesity (108 000 in 200321), such studies to define the
prevalence of hyperoxaluria after RYGB are clearly needed. The
cross-sectional data also indicate that hyperoxaluria is not
present in the majority of patients at 6 months after surgery, nor
was hyperoxaluria common in those stone patients that
presentedo6 months after surgery. The reasons are not certain,
but could involve dietary changes over time after RYGB.
A very recent report lists urinary tract calculus as a
common cause for emergency room visits (3.6%) and
readmission to hospital (3.0%) within the first 180 days
after bariatric surgery.48 However, the incidence of renal
stones over the course of many years after this procedure is
also unclear. Our study suggests that the risk may be clinically
important, especially in the group undergoing a distal
malabsorptive RYGB, as our previous study revealed that
16% of distal RYGB patients developed a stone after a mean
of 48 months since the surgery (range 12–148 months).22 It is
notable that a high percentage of the stone patients had pre-
existing stones (32%). We are not able to provide any
accurate estimate of the risk of stone occurrence after the
procedure, as the larger group of patients undergoing the
standard RYGB were not surveyed to identify stone events not
treated at Mayo Clinic. However, as the average number of
stone events among those with a pre-existing stones was only
1.3, it seems less likely that the cases we now report after
RYGB simply represent the natural history of an underlying
stone diathesis. In long-term follow-up of a large cohort
patients after jejuno-ileal bypass from a single center, the
cumulative incidence of renal stones over 15 years was 29%,
whereas the cumulative incidence of renal insufficiency was
9% over the same time period.49 Indeed, oxalate deposition
in the renal parenchyma leading to renal failure followed by
systemic oxalosis was a known complication after jejuno-ileal
bypass49 and there is a case report of this complication after
RYGB.22 Therefore, the prevalence of clinical renal disease
after RYGB, including nephrolithiasis, could potentially
increase over time as more patients are operated on and
accrue time at risk after surgery. If the incidence and severity
of enteric hyperoxaluria in this study is confirmed in
prospective evaluation of larger numbers of patients,
preventative treatment strategies may be necessary in all
patients following RYGB. At this point, we recommend that
all patients who develop renal stones after RYGB have prompt
metabolic evaluation and potential treatment for stone
prevention. Although increased risk for hyperoxaluria or
nephrolithiasis should be considered during the preoperative
assessment for RYGB, we would not currently consider this a
contraindication for the procedure.
In conclusion, hyperoxaluria is common among patients
after RYGB, especially those more than 6 months after the
procedure, and is a risk for CaOx-stone formation. Further,
patients may present with stones even in the first 6 months
after RYGB, often manifesting with markedly increased
urinary CaOx SS owing to a combination of lower volumes
and more modest hyperoxaluria. Effective measures to reduce
urinary oxalate excretion will be necessary to reduce urinary
SS and hence stone recurrence rate in this patient population.
Further studies are needed to define the incidence of these
urinary changes and stone formation as well as the cause of
hyperoxaluria in the RYGB population.
MATERIALS AND METHODS
All patients seen at Mayo Clinic, Rochester, since 1985 who had been
diagnosed with nephrolithiasis, oxalate nephropathy, or enteric
hyperoxaluria were identified as described previously.22 This patient
list was queried to identify all patients with a diagnoses of obesity or
RYGB, including all patients contained in a clinical database of
consecutive patients who have undergone bariatric surgery at Mayo
Clinic, Rochester, between 1985 and October 2004 (n¼ 1436).
Additional patients in the Mayo system suffering nephrolithiasis
after RYGB were identified via a mail-out survey sent to that subset
of patients having undergone distal RYGB at our institution and
from a query of diagnoses of patients referred to the Mayo Stone
Clinic through early 2006. Table 1 shows breakdown of patients. The
complete Mayo Clinic records were reviewed to confirm that
patients had undergone RYGB at Mayo or elsewhere and to verify
the presence of symptomatic nephrolithiasis after the procedure. In
this manner, a total of 60 patients were identified who suffered
nephrolithiasis events after RYGB and form the basis of this report.
A cross-sectional study was also completed among patients seen
in the Mayo Endocrinology Clinic for RYGB surgery. Patients
routinely undergo a complete preoperative assessment as well as 6-
and 12-month follow-up visits. Patients were randomly recruited
over the course of several weeks to collect 24-h urine SS studies in
order to represent all time periods.
For each patient, the medical record was abstracted for the
following information: age at time of RYGB, BMI at RYGB and at
time of occurrence of symptomatic nephrolithiasis, history of pre-
RYGB kidney stones, number of stones pre- and post-RYGB, time to
development of first stone post-RYGB, number of stones per year,
and interventions required. The type of bariatric procedure was also
classified as a standard RYGB with o150 cm Roux limb length50 or
distal RYGB (also termed a very, very long limb RYGB),
a modification of RYGB establishes a short common channel
of o125 cm distal ileum within which all enzymatic digestion
of complex carbohydrates, proteins, and fats occurs and thus has
malabsorptive components.51 Additionally, we captured all available
laboratory studies including serum creatinine concentration,
creatinine clearance, and 24-h urine studies (including volume,
pH, total excretions of citrate, oxalate, sodium, potassium, calcium,
phosphorous, UA, chloride, creatinine, sulfate, and magnesium, and
SS of CaOx, brushite, apatite, UA, and sodium urate). Reference
means were obtained from a normal value study conducted in non-
stone-forming adults. Follow-up 24-h urine studies were also
captured after treatments that included diet alone (low oxalate,
generous calcium, low fat, increased fluids), or diet combined with
medications including oxalate binders.
Patient demographics and biochemical information were ana-
lyzed using the JMP software package (SAS Institute, Cary, NC,
USA). Results are expressed as means7s.d. and box plots for each
106 Kidney International (2007) 72, 100–107
o r i g i n a l a r t i c l e MK Sinha et al.: Nephrolithiasis after RYGB
patient group. Po0.05 were deemed significant for comparison
t-tests.
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